ClinicalTrials.gg
CompletedNCT00984789Updated Apr 2, 2014

Birth Control Patch Study

A Phase 3 interventional study of Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016) and Norelgestromin/Ethinylestradiol (EVRA) in Contraception, sponsored by Bayer. Completed at 23 sites in 3 countries. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-04-02.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
393
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies in Hemorrhage with a site in Austria — 4 open to participants now, 4 under way, 1 of them phase 3. Hemorrhage · Austria.

Enrollment
6th of 23
393 · median 100
Started
2009
with 1 other
Phase 3
9 of 28
1 open now
Registered
6th of 28
by date
Lead sponsor
1 of 28
Bayer

Among the 28 studies in Hemorrhage with a site in Austria, this one is the 6th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2009, is one of 9 in phase 3, and was the 6th registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

4 of the 28 studies in Hemorrhage with a site in Austria are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 35 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Hemorrhage with a site in Austria, or all of them as a file.
02

Study summary

400 healthy women needed contraception will be asked to participate in this study. Half will be given EVRA, half will be given FC Patch low. They will be expected to apply the patches for 21 days of their cycle, for 7 cycles in total. The study will compare the patterns of menstrual bleeding on these two treatments, plus how effective they are at preventing pregnancy, general safety, and their acceptability to the participants.

03

Conditions studied

  • Contraception

Browse trials for

Keywords

  • Transdermal Patch
  • Bleeding
  • Pregnancy
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy women requesting aged 18-35 years old
  • Smokers must not be older than 30 at time of
  • History of regular cyclic menstrual periods, normal cervical smear

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Obesity (>30), to any ingredients of the study drug, significant skin reaction to transdermal preparations, any diseases/conditions that can compromise the functions of the body system (resulting in altered absorption/accumulation/ metabolism/excretion of the study drug), any diseases / conditions that may worsen under hormonal treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
393 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)

  • Active comparator
    Arm 2

    Drug: Norelgestromin/Ethinylestradiol (EVRA)

Interventions

06

What researchers measure

Primary outcomes

  1. Bleeding Patterns and cycle control

    Time frame: 7 cycles (each consisting of 28 days)

Secondary outcomes

  1. Contraceptive efficacy

    Time frame: 7 cycles (each consisting of 28 days) + follow up period of 14 days

  2. Adverse Event Collection

    Time frame: 7 cycles (each consisting of 28 days)

  3. Population pharmacokinetics

    Time frame: 7 cycles (each consisting of 28 days)

  4. Compliance to treatment

    Time frame: 7 cycles (each consisting of 28 days)

  5. Subjective assessment of treatment

    Time frame: 7 cycles (each consisting of 28 days)

07

Study locations

23 sites
  • Mödling, Niederösterreich 2340, Austria
  • Wiener Neustadt, Niederösterreich 2700, Austria
  • Graz, Steiermark 8036, Austria
  • Wörgl, Tirol 6300, Austria
  • Bregenz, Vorarlberg 6900, Austria
  • Graz, 8010, Austria
  • Innsbruck, 6020, Austria
  • Wien, 1050, Austria
  • Wien, 1090, Austria
  • Zeltweg, 8740, Austria
  • Brno, 602 00, Czech Republic
  • Ceske Budejovice, 37001, Czech Republic
  • Hradec Kralove, 500 02, Czech Republic
  • Olomouc, 77900, Czech Republic
  • Pisek, 39701, Czech Republic
  • Praha 10, 109 00, Czech Republic
  • Praha 2, 120 00, Czech Republic
  • Praha 7, 170 00, Czech Republic
  • Praha, 13000, Czech Republic
  • De Bilt, 3731 DN, Netherlands
  • Den Helder, 1782 GZ, Netherlands
  • Heerlen, 6401 MB, Netherlands
  • Nijmegen, 6525 EC, Netherlands
08

References and documents

Publications

  • Gruber D, Skrivanek A, Serrani M, Lanius V, Merz M. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study. Contraception. 2015 Feb;91(2):105-12. doi: 10.1016/j.contraception.2014.10.003. Epub 2014 Oct 13. PubMed 25453582 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2009
First posted
Sep 25, 2009
Start
May 2009
Primary completionActual
Sep 2010
CompletionActual
Sep 2010
Last update
Apr 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00984789
Lead sponsor
Bayer
Collaborators
Parexel
Responsible party
Sponsor
First posted
Sep 25, 2009
Start date
May 2009
Primary completion
Sep 2010
Completion
Sep 2010
Last update
Apr 2, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ethinyl Estradiol · Gestodene

Start the discussion